ALX ONCOLOGY HOLDINGS INC 8-K

What Happened ALX Oncology Holdings Inc. announced that Corey Goodman, Ph.D., resigned as Chairman and as a member of the Board effective at the close of business on June 29, 2026. The filing states Dr. Goodman resigned for personal reasons and not due to any disagreement with the Company. The Board immediately appointed independent director Scott Garland to serve as Chairman, effective June 29, 2026. The company issued a press release on June 30, 2026, confirming these changes.

Key Details

• Resignation: Corey Goodman, Ph.D., resigned as Chairman and director effective June 29, 2026 (personal reasons; no disagreement with the company).
• New Chair: Scott Garland, an independent director, was appointed Chairman effective June 29, 2026.
• Board committees updated:
  • Audit Committee: Rekha Hemrajani (Chair); Daniel J. Curran, M.D.; Scott Garland.
  • Compensation Committee: Chris Takimoto, M.D., Ph.D., F.A.C.P. (Chair); Scott Garland.
  • Corporate Governance & Nominating Committee: Daniel J. Curran, M.D. (Chair); Rekha Hemrajani.
• Disclosure: Press release dated June 30, 2026 filed as Exhibit 99.1 to the Form 8‑K.

Why It Matters Board leadership changes are a governance event investors watch because the Chair helps set board priorities and oversight focus. The appointment of an independent director (Scott Garland) as Chair and the named committee chairs indicate who will lead audit and compensation oversight going forward. The filing notes no disagreement with management, which suggests the change was not due to a public governance dispute; investors should monitor subsequent disclosures for any strategic or governance shifts.